Patents
Sitemap › C07 - Organic chemistry › C07D - Heterocyclic compounds › C07D 295 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
Patents for C07D 295 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms (34,005)
12/2005
12/15/2005CA2561858A1 Arylsulfonamides and uses related thereto
12/14/2005EP1603911A1 Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators
12/14/2005EP1534283B1 Formulation of liposomal derivatives of phenylalanine
12/14/2005EP1263712B1 3-(2,5-diaminophenyl)-acrylamide derivatives and colouring agents containing said compounds
12/14/2005EP1224165B1 Novel compounds
12/14/2005EP1200411B1 Process for synthesis of heteroaryl-substituted urea compounds
12/14/2005CN1708489A 1-(4-benzyl-piperazin-1-yl)-3-phenyl-propenone derivatives
12/14/2005CN1708488A Improvement in the storage stability of photoinitiators
12/14/2005CN1708476A Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds
12/14/2005CN1231464C Novel 3-substituted urea derivatives and medicinal use thereof
12/14/2005CN1231458C Novel aryloxy-alkyl-dialkylamines compound
12/14/2005CN1231439C Novel hydronaphtalene compounds prepared by phodium catalyzed ring opening reaction in presence of phosphine ligand
12/14/2005CN1231212C Multicyclic compounds which inhibit beukocyte adhesion mediated by VLA-4
12/13/2005US6974876 Method for preparing intermediates useful in synthesis of retroviral protease inhibitors
12/13/2005US6974836 Diamines as modulators of chemokine receptor activity
12/13/2005US6974817 CCR1 receptor antagonists; inhibitors of MIP-1 alpha (CCL3) binding to its receptor CCR1 found on inflammatory and immunomodulatory cells; macrophage inflammatory protein (MIP)
12/13/2005US6974812 such as 2-chloro-N-(1-hydroxy-cycloheptylmethyl)-5-[4-(2-hydroxy-3-methoxy-propyl)-3,5-dioxo-4,5-dihydro-3H-[1,2,4]triazin-2-yl]-benzamide; purinergic receptors (P2x7 E); for treatment of interleukin-1 associated disorders (rheumatoid arthritis)
12/08/2005WO2005115983A1 Aryl sulfonamide and sulfonyl compounds as modulators of ppar and methods of treating metabolic disorders
12/08/2005WO2005115972A1 Therapeutic compounds
12/08/2005WO2005115969A1 Method for producing quaternary ammonium compounds
12/08/2005WO2005115361A2 Androgen receptor modulators and method of treating disease using the same
12/08/2005WO2005034940A3 Dual alanyl aminopeptidase and dipeptidyl peptidase iv inhibitors for functionally influencing different cells and for treating immunological, inflammatory, neuronal and other diseases
12/08/2005WO2004099126A8 N-(2-PHENYLETHYL)SULFAMIDE DERIVATIVES AS INTEGRIN α4 ANTAGONISTS
12/08/2005US20050272815 Compounds and compositions for delivering active agents
12/08/2005US20050272774 Substituted cyclohexane derivatives
12/08/2005US20050272745 Novel piperidine and piperazine derivatives
12/08/2005US20050272744 N-((4-((( 1R)-3 -(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)-4-(4-(2-fluorobenzyl)-4-methoxy-1-piperidinyl)benzenecarboximidamide; trigger apoptosis through the inhibition of the Bcl family of proteins
12/08/2005US20050272036 Ketones
12/08/2005DE102004023529A1 Verfahren zur kontinuierlichen Herstellung eines Amins Process for the continuous preparation of an amine
12/08/2005CA2566942A1 Androgen receptor modulators and method of treating disease using the same
12/08/2005CA2566011A1 Method for producing quaternary ammonium compounds
12/08/2005CA2565066A1 Therapeutic compounds
12/08/2005CA2564638A1 Aryl sulfonamide and sulfonyl compounds as modulators of ppar and methods of treating metabolic disorders
12/07/2005EP1602642A1 Imino ether derivative compounds and drugs containing the compounds as the active ingredient
12/07/2005EP1602368A2 Cdc25 phosphatase inhibitors
12/07/2005EP1601650A2 Process for preparing 2-methylpyrrolidine and specific enantiomers thereof
12/07/2005EP1601643A1 Arylcycloalkyl derivatives with branched side chains as ppar receptor modulators, method for their production and their use as medicaments
12/07/2005EP1601356A1 Crystalline non-solvated 1-(4-(2-piperidinylethoxy)phenoxy)-2-(4-methanesulfonylphenyl)-6-hydroxynaphthalene hydrochloride
12/07/2005EP1077928B1 Novel substituted cyclic compounds, preparation method and pharmaceutical compositions containing them
12/07/2005EP1077927B1 Novel substituted cyclic compounds, preparation method and pharmaceutical compositions containing them
12/07/2005CN1705635A Inhibitors of histone deacetylase
12/07/2005CN1230416C Pharmaceutical compounds
12/06/2005US6972343 such as N,N'-diformyl-N,N'-di[1-methyl-2-S-thiobenzoyl-4-methoxybut-1-enyl]-1,12-diaminododecane; for treatment of malaria
12/06/2005US6972340 For therapy of diabetes, obesity, autoimmune disorders, acute and chronic inflammatory disorders, osteoporosis, cancer, malignant disorders
12/06/2005US6972300 Compounds and compositions for delivering active agents
12/06/2005US6972295 Central nervous system disorders; psychological disorders; antiinflammatory agents; multiple sclerosis
12/06/2005US6972290 Piperazine derivatives and their use as anti-inflammatory agents
12/06/2005US6972287 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits
12/06/2005CA2235840C Phenylethanolamine compounds useful as .beta.3 agonist, process for producing the same, and intermediates in the production of the same
12/06/2005CA2206787C 2,5-diamino-3,4-disubstituted-1,6-diphenylhexane isosteres comprising benzamide, sulfonamide and anthranilamide subunits and methods of using same
12/06/2005CA2148593C Use of piperazine derivatives for the treatment of cognitive disorders
12/06/2005CA2096528C Retroviral protease inhibitors
12/01/2005WO2005113527A1 Tetrahydronaphthyl- piperazines as 5-ht1b antagonists, inverse agonists and partial agonists
12/01/2005WO2005113526A2 Metabolites of 4-(3,4-dichloro-phenyl)-2-[2-(4-methyl-piperazin-1-yl)-benzylidene]-thiomorpholin-3-one
12/01/2005WO2005077899A3 Amino-substituted tricyclic derivatives and methods of use
12/01/2005WO2005060456A3 Method for treating adamts-5-associate disease
12/01/2005WO2005042516A3 Ligands of melanocortin receptors and compositions and methods related thereto
12/01/2005US20050267214 Containing a quinolinecarbonylalkyl group, e.g., N1-[3-[(butylamino)sulfonyl](2-methylpropyl)amino]-2R-hydroxy-1S-(phenylmethyl)propyl]-2S-[(2-quinolinylcarbonyl) amino]butanediamide
12/01/2005US20050267183 Selective estrogen receptor modulators
12/01/2005US20050267168 Pentanoic acid derivatives
12/01/2005US20050267167 Pentanoic acid derivatives
12/01/2005US20050267152 Gly1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders
12/01/2005US20050267129 Dipeptide nitrile cathepsin K inhibitors
12/01/2005US20050267127 Guanidino phenylalanin compounds used as urokinase inhibitors
12/01/2005US20050267126 Compounds derived from aryl carbamates, preparation thereof and uses of same
12/01/2005US20050267121 Aralkyl-alcohol peiperazine derivatives adn their uses as antidepressant
12/01/2005US20050267094 glucosyl ceramide inhibitors lower glycosphingolipid levels; anticarcinogenic, antitumor agents; angiogenesis inhibitors; tumor antigens
12/01/2005US20050267043 Novel inhibitors of hepatitis C virus NS3 protease
12/01/2005US20050267003 Succinic acid semi-amides as anti-corrosives agents
12/01/2005US20050266567 Methods for generating high titer helper-free preparations of released recombinant AAV vectors
12/01/2005US20050265961 Biodegradable poly(beta-amino esters) and uses thereof
12/01/2005DE102004023522A1 Substituierte Cyclohexyl-1,4-diamin-Derivate Substituted cyclohexyl-1,4-diamine derivatives
12/01/2005CA2566934A1 Tetrahydronaphthyl- piperazines as 5-ht1b antagonists, inverse agonists and partial agonists
11/2005
11/30/2005EP1599468A1 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
11/30/2005EP1465892A4 Glycinamides as factor xa inhibitors
11/30/2005EP1274457B1 Method and compositions for the treatment of allergic conditions using pgd2 receptor antagonists
11/30/2005EP1098864B9 Method for hydrogenating unsaturated heterocyclic compounds
11/30/2005EP1064268B1 Novel cationic compounds, their use as coupling agents for oxidation dyeing of keratinous fibres, dyeing compositions and dyeing methods
11/30/2005EP0925291B1 Spirocyclic dopamine receptor subtype ligands
11/30/2005CN1703401A Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues
11/30/2005CN1703395A Aryl and heteroaryl compounds and methods to modulate coagulation
11/30/2005CN1703393A Spiro compounds, medicinal compositions containing the same and intermediates of the compounds
11/30/2005CN1229373C Piperidinee derivatives as neurokinin1 antagonists
11/30/2005CN1229345C N-(indolcarbonyl) piperazin derivatives
11/30/2005CN1229343C Chemotactic factor receptor active regulator
11/30/2005CN1229330C N-arylating method using amino-acid as additives
11/30/2005CN1229102C Novel couplers for use in oxidative hair dyeing
11/29/2005US6969728 Antiinflammatory agents
11/29/2005US6969713 Piperidine and piperazine acetamide derivatives
11/29/2005US6969710 Compounds
11/24/2005WO2005111050A2 Enantioselective phosphoramidite compounds and catalysts
11/24/2005WO2005110992A1 Amido compounds and their use as pharmaceuticals
11/24/2005WO2005110980A2 Aryl sulfones and uses related thereto
11/24/2005WO2005110978A1 Process for producing urethane (meth)acrylates and new urethane (meth)acrylates
11/24/2005WO2005110974A1 Substituted cyclohexyl-1,4-diamine derivatives
11/24/2005WO2005110969A1 Method for the continuous production of an amine
11/24/2005WO2005110413A2 Medicaments containing n-sulfamoyl-n'-arylpiperazines for the prophylaxis or treatment of obesity and related conditions
11/24/2005WO2005092011A3 Mitotic kinesin inhibitors
11/24/2005WO2005077884A3 Hydroaminomethylation of olefins
11/24/2005US20050261501 e.g. 1-({[9-(hydroxymethyl)-3-oxaspiro[5.5]undec-9-yl]amino}acetyl)-2-pyrrolidinecarbonitrile; dipeptidyl-peptidase IV inhibitor; antidiabetic, hypoglycemic agent; non-insulin dependent diabetes, obesity
1 ... 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 ... 341